“The monoclonal antibodies rituximab, ocrelizumab, ofatumumab (Kesimpta), and ublituximab (Briumvi) provide outstanding ...
Sibeprenlimab gains accelerated approval from the FDA for IgA nephropathy, showing significant proteinuria reduction and ...
Eleanor Perfetto, PhD, explores how most favored nation policy relates to broader drug pricing and cost-effectiveness debates ...
In the KEYNOTE-B96 trial ( NCT05116189 ), weekly paclitaxel with bevacizumab and pembrolizumab (Keytruda; Merck) demonstrated ...
Among adults surveyed, 27.8% (95% CI, 25.7-29.8) received all telemental health care, 21.5% (95% CI, 19.8-23.1) received ...
Key End Points for Providers to Consider With New Multiple Myeloma Therapies: Hearn Jay Cho, MD, PhD
Hearn Jay Cho, MD, PhD, chief medical officer at the Multiple Myeloma Research Foundation, shared insights on what end points ...
Zachary Contreras from Sharp Health Plan explains how managed care organizations can support early adoption of DM-BUP to ...
While limited data suggest loncastuximab tesirine plus rituximab may be active in the third line, larger cohorts and ...
Zachary Contreras from Sharp Health Plan discusses findings from the AMCP Nexus study showing that dextromethorphan-bupropion ...
Nerandomilast, a PDE4B inhibitor, is a new treatment option for IPF, showing better tolerability than nintedanib and ...
Patients with chronic spontaneous urticaria (CSU) experienced improved quality of life and sleep when symptoms were mitigated ...
Combining genetic features with clinical data improved the performance of a pulmonary fibrosis prediction score for people with rheumatoid arthritis. A new combined risk score that incorporates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback